Open AccessModern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
Author(s) -
I V Poddubnaya,
Поддубная Ирина Владимировна,
Е А Барях,
Барях Елена Александровна,
S. Voloshin,
Волошин Сергей Владимирович,
Liliya Gorenkova,
Горенкова Лилия Гамилевна,
Kamil Kaplanov,
Капланов Камиль Даниялович,
Alla M. Kovrigina,
Ковригина Алла Михайловна,
N. Mikhailova,
Михайлова Наталия Борисовна,
Т. И. Поспелова,
Поспелова Татьяна Ивановна,
В. В. Птушкин,
Птушкин Вадим Вадимович,
Г. С. Тумян,
Тумян Гаяне Сергеевна,
N. A. Falaleeva,
Фалалеева Наталья Александровна,
Gulnara N. Khusainova,
Хусаинова Гульнара Наилевна
Publication year - 2021
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2021.1.200698
Subject(s) - brentuximab vedotin , medicine , chop , oncology , regimen , anaplastic large cell lymphoma , peripheral t cell lymphoma , cd30 , cyclophosphamide , lymphoma , t cell , immunology , chemotherapy , immune system
Relevance. Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative malignancies that account for approximately 10% of adult non-Hodgkins lymphomas. Despite the variety of PTCL subtypes, CHOP-like regimens are the standard first-line therapy in most cases. At the same time, the level of complete remissions at the using these schemes is about 39%, the 2-year event-free survival rate does not exceed 45%. The possibilities of subsequent therapy of patients are very limited: the median overall survival after relapse is only 6.5 months. The most significant results were obtained only in patients with relapses of anaplastic large cell lymphoma after the use of the targeted drug brentuximab vedotin BV (conjugate of a CD30-directed monoclonal antibody and an antitumor agent). Given the favorable safety profile of this drug, a phase 3, double-blind, randomized study (ECHELON-2) was initiated and conducted comparing the efficacy and safety of the combination of BV with CHP (cyclophosphamide, doxorubicin, prednisolone) (BV+CHP) and standard CHOP regimen in previously untreated patients with CD30-positive PTCL.
Aim. Discuss the entire spectrum of unmet medical needs in the treatment of patients with PTCL and adapt existing approaches taking into account new therapeutic options (results of the protocol ECHELON-2).
Results. The advantages of the BV+CHP regimen in the treatment of previously untreated patients with CD30-positive PTCL were recognized as convincing. Given the lack of real therapeutic options, it is recommended to register in Russia a broad indication for BV: treatment of previously untreated CD30-expressing peripheral T-cell lymphomas (in combination with CHP). It was considered expedient to include the BV+CHP regimen in the updated Clinical Guidelines for the Treatment of Lymphoproliferative Diseases.